Bristol Myers Squibb (BMY) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $60.57, +2.18% vs the prior close of $59.28.
- Volume 13.75M shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BMY rises 2.2% to $60.57. Closed at $60.57, +2.18% vs the prior close of $59.28. Day range $60.39–$62.25, opened at $60.67.
BMY daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — BMY rises 2.2% to $60.57
- Closed at $60.57, +2.18% vs the prior close of $59.28. Day range $60.39–$62.25, opened at $60.67.
- Volume was 13.75M shares, 1.3x its 50-day average of 10.89M.
- Price is -4.8% vs its 50-day average ($63.59) and +1.6% vs its 200-day average ($59.61).
- 52-week range $42.52–$68.64; today's close sits at 69% of that range, 11.8% below the 52-week high.
Oct 14, 2026 — BMY jumps 4.6% to $59.28
- Closed at $59.28, +4.61% vs the prior close of $56.67. Day range $56.58–$59.39, opened at $56.81.
- Volume was 14.05M shares, 1.3x its 50-day average of 11.07M.
- Price is -6.9% vs its 50-day average ($63.66) and -0.5% vs its 200-day average ($59.58).
- 52-week range $42.52–$68.64; today's close sits at 64% of that range, 13.6% below the 52-week high.
Oct 13, 2026 — BMY dips 1.6% to $56.67, a 3-month low, 4 down days in a row
- Closed at $56.67, -1.58% vs the prior close of $57.58. Day range $56.15–$58.02, opened at $57.78.
- Volume was 16.96M shares, 1.5x its 50-day average of 11.40M.
- Price is -11.2% vs its 50-day average ($63.79) and -4.8% vs its 200-day average ($59.56).
- 52-week range $42.52–$68.64; today's close sits at 54% of that range, 17.4% below the 52-week high.
- That makes 4 straight losses.
Oct 12, 2026 — BMY dips 2.6% to $57.58, a 1-month low on 2.0x normal volume
- Closed at $57.58, -2.60% vs the prior close of $59.12. Day range $56.72–$60.68, opened at $60.11.
- Volume was 22.56M shares, 2.0x its 50-day average of 11.24M — unusually heavy trading.
- Price is -10.0% vs its 50-day average ($63.96) and -3.3% vs its 200-day average ($59.55).
- 52-week range $42.52–$68.64; today's close sits at 58% of that range, 16.1% below the 52-week high.
- That makes 3 straight losses.
Oct 9, 2026 — BMY dips 0.8% to $59.12
- Closed at $59.12, -0.77% vs the prior close of $59.58. Day range $58.74–$59.79, opened at $58.88.
- Volume was 9.25M shares, 0.8x its 50-day average of 11.41M.
- Price is -7.8% vs its 50-day average ($64.12) and -0.7% vs its 200-day average ($59.53).
- 52-week range $42.52–$68.64; today's close sits at 64% of that range, 13.9% below the 52-week high.
Oct 8, 2026 — BMY ends flat (-0.2%) to $59.58
- Closed at $59.58, -0.20% vs the prior close of $59.70. Day range $58.73–$59.94, opened at $59.10.
- Volume was 13.07M shares, 1.2x its 50-day average of 11.36M.
- Price is -7.2% vs its 50-day average ($64.23) and +0.1% vs its 200-day average ($59.51).
- 52-week range $42.52–$68.64; today's close sits at 65% of that range, 13.2% below the 52-week high.
Oct 7, 2026 — BMY ends flat (+0.2%) to $59.70
- Closed at $59.70, +0.18% vs the prior close of $59.59. Day range $59.01–$60.10, opened at $59.45.
- Volume was 11.09M shares, 1.0x its 50-day average of 11.44M.
- Price is -7.2% vs its 50-day average ($64.30) and +0.4% vs its 200-day average ($59.48).
- 52-week range $42.52–$68.64; today's close sits at 66% of that range, 13.0% below the 52-week high.
Oct 6, 2026 — BMY rises 1.3% to $59.59
- Closed at $59.59, +1.33% vs the prior close of $58.81. Day range $58.64–$59.60, opened at $58.94.
- Volume was 9.89M shares, 0.9x its 50-day average of 11.45M.
- Price is -7.4% vs its 50-day average ($64.38) and +0.2% vs its 200-day average ($59.45).
- 52-week range $42.52–$68.64; today's close sits at 65% of that range, 13.2% below the 52-week high.
Oct 5, 2026 — BMY slides 3.8% to $58.81, a 1-month low, 5 down days in a row
- Closed at $58.81, -3.83% vs the prior close of $61.15. Day range $58.33–$60.15, opened at $59.89.
- Volume was 19.24M shares, 1.7x its 50-day average of 11.31M.
- Price is -8.7% vs its 50-day average ($64.44) and -1.0% vs its 200-day average ($59.42).
- 52-week range $42.52–$68.64; today's close sits at 62% of that range, 14.3% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — BMY dips 0.5% to $61.15, 4 down days in a row
- Closed at $61.15, -0.50% vs the prior close of $61.46. Day range $60.24–$61.24, opened at $60.66.
- Volume was 9.93M shares, 0.9x its 50-day average of 11.26M.
- Price is -5.2% vs its 50-day average ($64.51) and +3.0% vs its 200-day average ($59.40).
- 52-week range $42.52–$68.64; today's close sits at 71% of that range, 10.9% below the 52-week high.
- That makes 4 straight losses.
BMY latest news & SEC filings
Every SEC filing by or about BMY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gallman Cari converted options/RSUs into 4,559 shares on Oct 2, 2026; now holds 18,208
- Gallman Cari had withheld for taxes 2,332 shares at $61.15 (≈$142.60K) on Oct 2, 2026; now holds 15,876
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 30, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $12.97B (prior year $12.27B) (+5.7% vs Jun 30, 2025)
- Net income: $3.32B (prior year $1.31B) (+153.2% vs Jun 30, 2025)
- Diluted EPS: $1.62 (prior year $0.64) (+153.1% vs Jun 30, 2025)
Jul 30, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade BMY
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 5, 2026, Oct 30, 2025. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.47% (largest 4.6%).
- Liquidity: about 14.83M shares (≈$898.32M) trade per day on average.
- 52-week position: $60.57 vs a range of $42.52–$68.64 (69% of the range).
- Dividends: last ex-dividend date Oct 2, 2026 ($0.63/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 4 sales; latest: Cristian Massacesi sold 6,249 shares on Sep 9, 2026.
- Latest filings: 10-Q Jul 30, 2026; 8-K Jul 30, 2026; 8-K May 8, 2026.
- Share count: 2.04B shares outstanding (Jul 22, 2026), +0.4% vs a year earlier.
- Listing: NYSE · industry: Pharmaceutical Preparations.
BMY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 60.67 | 62.25 | 60.39 | 60.57 | 13.75M |
| Oct 14, 2026 | 56.81 | 59.39 | 56.58 | 59.28 | 14.05M |
| Oct 13, 2026 | 57.78 | 58.02 | 56.15 | 56.67 | 16.96M |
| Oct 12, 2026 | 60.11 | 60.68 | 56.72 | 57.58 | 22.56M |
| Oct 9, 2026 | 58.88 | 59.79 | 58.74 | 59.12 | 9.25M |
| Oct 8, 2026 | 59.10 | 59.94 | 58.73 | 59.58 | 13.07M |
| Oct 7, 2026 | 59.45 | 60.10 | 59.01 | 59.70 | 11.09M |
| Oct 6, 2026 | 58.94 | 59.60 | 58.64 | 59.59 | 9.89M |
| Oct 5, 2026 | 59.89 | 60.15 | 58.33 | 58.81 | 19.24M |
| Oct 2, 2026 | 60.66 | 61.24 | 60.24 | 61.15 | 9.93M |
| Oct 1, 2026 | 62.20 | 62.61 | 61.25 | 61.46 | 10.77M |
| Sep 30, 2026 | 63.28 | 64.13 | 62.40 | 62.40 | 15.87M |
| Sep 29, 2026 | 63.58 | 63.89 | 61.95 | 62.86 | 15.84M |
| Sep 28, 2026 | 62.77 | 63.93 | 62.30 | 63.88 | 14.02M |
| Sep 25, 2026 | 61.75 | 62.91 | 61.40 | 62.86 | 10.67M |
| Sep 24, 2026 | 61.40 | 61.59 | 60.60 | 61.50 | 14.90M |
| Sep 23, 2026 | 62.31 | 62.65 | 61.08 | 61.15 | 15.84M |
| Sep 22, 2026 | 62.73 | 63.08 | 62.03 | 62.25 | 15.24M |
| Sep 21, 2026 | 63.09 | 63.40 | 62.62 | 62.62 | 6.84M |
| Sep 18, 2026 | 62.71 | 63.07 | 62.19 | 63.06 | 36.85M |
About Bristol Myers Squibb
Bristol Myers Squibb (BMY) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PRINCETON, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 14272.
BMY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Peter J Arduini | Director | Jul 2, 2026 |
| Christopher S. Boerner | Chief Executive Officer | Mar 12, 2026 |
| Deepak Bhatt | Director | Feb 3, 2026 |
| Julia A Haller | Director | Jun 16, 2026 |
| Medina Manuel Hidalgo | Director | Feb 3, 2026 |
| Michael R. Mcmullen | Director | Jul 2, 2026 |
| Paula A Price | Director | Feb 3, 2026 |
| Derica W Rice | Director | Jul 2, 2026 |
| Theodore R. Ii Samuels | Director | Jul 2, 2026 |
| Karen H Vousden | Director | Feb 3, 2026 |
| Phyllis R Yale | Director | Jul 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christopher S. Boerner | Chief Executive Officer | Mar 12, 2026 |
| David V Elkins | EVP, Chief Financial Officer | Apr 2, 2026 |
| Cari Gallman | EVP, General Counsel | Aug 4, 2026 |
| Benjamin Hickey | President, RayzeBio Org. | Mar 12, 2026 |
| Lynelle Hoch | President, Cell Therapy Org. | Mar 12, 2026 |
| Phil M Holzer | SVP and Controller | Aug 26, 2026 |
| Adam Lenkowsky | EVP, Chief Commercial Officer | May 5, 2026 |
| Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | Sep 10, 2026 |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | Mar 12, 2026 |
| Robert M Plenge | EVP, Chief Research Officer | Mar 12, 2026 |
| Ahn Amanda Poole | EVP, Chief People Officer | Mar 12, 2026 |
| Karin Shanahan | EVP, Chief Supply Chain & Ops | Apr 2, 2026 |
| Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | Mar 12, 2026 |
| Bartie Wendy Short | EVP, Corporate Affairs | Sep 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 9, 2026 | Cristian Massacesi | Sale | 6,249 | $64.57 |
| Aug 25, 2026 | Phil M Holzer | Sale | 500 | $67.50 |
| Apr 1, 2026 | David V Elkins | Sale | 25,519 | $61.60 |
| Apr 1, 2026 | David V Elkins | Sale | 4,481 | $62.05 |
BMY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $48.19B | $7.05B | 3.46 | $14.16B |
| Dec 31, 2024 | $48.30B | $-8.95B | -4.41 | $15.19B |
| Dec 31, 2023 | $45.01B | $8.03B | 3.86 | $13.86B |
| Dec 31, 2022 | $46.16B | $6.33B | 2.95 | $13.07B |
| Dec 31, 2021 | $46.38B | $6.99B | 3.12 | $16.21B |
Latest balance sheet: total assets $87.63B, total liabilities $65.31B, cash $8.72B (as of Jun 30, 2026).
BMY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $64.86 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $60.59 |
| Feb 5, 2026 | 8-K Item 2.02 (results) | $59.52 |
| Oct 30, 2025 | 8-K Item 2.02 (results) | $45.62 |
| Jul 31, 2025 | 8-K Item 2.02 (results) | $43.31 |
| Apr 24, 2025 | 8-K Item 2.02 (results) | $48.69 |
| Feb 6, 2025 | 8-K Item 2.02 (results) | $57.42 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $55.77 |
| Jul 26, 2024 | 8-K Item 2.02 (results) | — |
| Apr 25, 2024 | 8-K Item 2.02 (results) | — |
| Feb 2, 2024 | 8-K Item 2.02 (results) | — |
| Oct 26, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on BMY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.